| 摘要 |
FIELD: pharmacology. ^ SUBSTANCE: invention concerns compounds of formula (I) , where A is optionally substituted monocyclic aryl and heteroaryl group, B is optionally substituted monocyclic nitrogen-containing heterocyclic group, and either a) R1 is hydrogen atom and R2 is group selected out of -NH2 and optionally substituted alkinyl group, or b) R2, R1 and -NH- group with linked R1 form fragment selected out of fragments of formulae , , and , where Ra is selected out of hydrogen atom and group selected out of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, -OR3, where R3 is independently selected out of group including hydrogen atom and lower alkyl or cycloalkyl groups, Rb is selected out of hydrogen atom and group selected out of optionally substituted alkyl or optionally substituted cycloalkyl group; application of claimed compounds in medicine obtainment for treatment of pathological states or diseases, the course of which is alleviated by antagonistic effect on adenosine receptor A2B, and pharmaceutical composition with antagonistic effect on adenosine receptor A2B. ^ EFFECT: compounds applicable in treatment of such diseases as asthma, bronchostenosis, allergic diseases, hypertension, atherosclerosis, reperfusion injury, myocardial ischemia, retinopathy, inflammation, gastrointestinal disorders related to cell proliferation, diabetes and/or autoimmune diseases. ^ 26 cl, 49 ex, 2 tbl |
